


RESEARCH

Open Access



Generational synaptic functions of GABA_A receptor $\beta 3$ subunit deteriorations in an animal model of social deficit

Ming-Chia Chu¹, Han-Fang Wu¹, Chi-Wei Lee¹, Yueh-Jung Chung¹, Hsiang Chi¹, Po See Chen^{3,4*} and Hui-Ching Lin^{1,2,5*} 

Abstract

Background: Disruption of normal brain development is implicated in numerous psychiatric disorders with neurodevelopmental origins, including autism spectrum disorder (ASD). Widespread abnormalities in brain structure and functions caused by dysregulations of neurodevelopmental processes has been recently shown to exert adverse effects across generations. An imbalance between excitatory/inhibitory (E/I) transmission is the putative hypothesis of ASD pathogenesis, supporting by the specific implications of inhibitory γ -aminobutyric acid (GABA)ergic system in autistic individuals and animal models of ASD. However, the contribution of GABAergic system in the neuropathophysiology across generations of ASD is still unknown. Here, we uncover profound alterations in the expression and function of GABA_A receptors (GABA_ARs) in the amygdala across generations of the VPA-induced animal model of ASD.

Methods: The F2 generation was produced by mating an F1 VPA-induced male offspring with naïve females after a single injection of VPA on embryonic day (E12.5) in F0. Autism-like behaviors were assessed by animal behavior tests. Expression and functional properties of GABA_ARs and related proteins were examined by using western blotting and electrophysiological techniques.

Results: Social deficit, repetitive behavior, and emotional comorbidities were demonstrated across two generations of the VPA-induced offspring. Decreased synaptic GABA_AR and gephyrin levels, and inhibitory transmission were found in the amygdala from two generations of the VPA-induced offspring with greater reductions in the F2 generation. Weaker association of gephyrin with GABA_AR was shown in the F2 generation than the F1 generation. Moreover, dysregulated NMDA-induced enhancements of gephyrin and GABA_AR at the synapse in the VPA-induced offspring was worsened in the F2 generation than the F1 generation. Elevated glutamatergic modifications were additionally shown across generations of the VPA-induced offspring without generation difference.

*Correspondence: chenps@mail.ncku.edu.tw; hclin7@nycu.edu.tw; huiching4372@gmail.com

¹ Department and Institute of Physiology, School of Medicine, National Yang Ming Chiao Tung University, Tainan 112, Taiwan

³ Department of Psychiatry, Institute of Behavioral Medicine, College of Medicine and Hospital, National Cheng Kung University Hospital, National Cheng Kung University, No. 138, Sheng-Li Road, Tainan 704, Taiwan

Full list of author information is available at the end of the article



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Conclusions: Taken together, these findings revealed the E/I synaptic abnormalities in the amygdala from two generations of the VPA-induced offspring with GABAergic deteriorations in the F2 generation, suggesting a potential therapeutic role of the GABAergic system to generational pathophysiology of ASD.

Keywords: GABA_AR, Excitatory/inhibitory imbalance, Gephyrin, Generational effect, Valproate, Autism spectrum disorder

Background

The prevalence of neurodevelopmental disorders has been dramatically risen worldwide during the last few decades [1, 2]. Early life disturbance in the brain is implicated in numerous psychiatric disorders with neurodevelopmental origins, including autism spectrum disorder (ASD). Recent evidence has strengthened the relationship between parental life experiences and offspring physiology [3, 4]. Environmental perturbations, such as parental stress, malnutrition, infection, or toxicants, increase the offspring susceptibility of ASD and other neurodevelopmental disorders [5–7]. Moreover, widespread abnormalities in brain structure and functions caused by disruptions of neurodevelopmental processes has been recently shown to enhance the incidence of disease and exert adverse effects across generations in both clinical and animal studies [7–12]. Several brain structures are highly influenced by parental mental health in subsequent generations of offspring, including the amygdala and hippocampus [13–15]. This includes the significant association between the amygdala and socio-emotional problems in individuals with ASD that has long been identified [16–19]. The altered excitatory and inhibitory synaptic functions in the amygdala are regarded as a leading cause of the autism phenotype [20, 21]. Therefore, uncovering the key hallmarks within a specific brain area underlying the cross-generational impact of ASD has become a matter of great urgency.

Excitatory/inhibitory (E/I) imbalance within the brain is one of the pathophysiological theories of ASD [22]. In line with this, both post-mortem and animal studies have observed abnormal dendritic spine morphology [23, 24] and altered levels of glutamate- and γ -aminobutyric acid (GABA)-related proteins in the brain tissue of patients or animals with ASD [25–29]. Recent evidence assessed by next-generation mRNA sequencing has revealed several transcriptional alterations in the glutamatergic signaling implicated in schizophrenia, bipolar disorder and ASD in the F1 and F2 generations of the offspring derived from immune-challenged ancestors [30]. Moreover, the transgenerational replicability of abnormal glutamatergic protein expressions has been demonstrated in an ASD model induced by prenatal VPA exposure [31]. Another key factor in the E/I balance is the essential role of the γ -aminobutyric acid (GABA)ergic system, which has

long been documented in ASD [32]. Specifically, the $\beta 3$ subunits of GABA_AR are vital for the proper functioning of various brain regions during neurodevelopment. Mutations or duplications of chromosome 15q11-13, a complex locus containing genes for the $\beta 3$ subunits of GABA_AR, is the most common chromosomal anomaly in cases of ASD [33–35]. Moreover, disruptions in the GABA_AR $\beta 3$ subunit have been emphasized for their direct contribution to the pathophysiology of ASD in animal models [36–38]. Collectively, these evidences increase the possibility that dysfunctions of the GABAergic system, especially the GABA_AR $\beta 3$ subunit, is a pathological hallmark of various neurodevelopmental diseases; therefore, elucidating its role in the cross-generational effects of ASD pathogenesis is necessary.

Accordingly, the present study aimed to investigate whether E/I alterations, specifically in GABAergic system, contribute to the cross-generational effects on the pathogenesis of ASD by using VPA-induced animal model of ASD. We generated a F2 generation of the VPA-induced offspring by mating the F1 VPA-induced male offspring with naïve females after a single injection of VPA on an embryonic day (E12.5) in F0. We show that both two generations of the VPA-induced offspring performed autistic behavioral phenotypes with synaptic aberrations in both excitatory and inhibitory systems in the amygdala. Intriguingly, greater reductions in the GABAergic tone in the F2 generation of the VPA-induced offspring were observed compared with the F1 generation in this animal model of ASD.

Methods

Animals

All experimental procedures complied with the National Institute of Health Guide for the Care and Use of Laboratory Animals (USA) and approved by the Institutional Animal Care and Use Committee at National Yang Ming Chiao Tung University with a project number 1091206n. Animals were housed in a controlled temperature (24 ± 1 °C) and humidity ($50 \pm 5\%$) under a 12 h light/dark schedule with food and water available ad libitum. Eight-to ten-week-old male and female Sprague Dawley (SD) rats were mated in pairs. Female rats were controlled every morning, and the presence of a vaginal plug was considered as embryonic day (E0.5). Single

intraperitoneal administration of 500 mg/kg sodium valproate (NaVPA) was delivered to pregnant rats on an E12.5 for producing F1 generation VPA-induced offspring, whereas the control group received sterile saline (500 mg/kg) as vehicle. F2 generation of VPA-induced offspring were generated by mating the male VPA-induced F1 offspring with naïve females (Additional file 1: Fig. S1a). Pregnant rats were housed individually and allowed to raise their own litters. Litter size was kept at 8–12 pups per dams by culling at postnatal day 3 (PND3) with even distribution between male and female. After weaning on PND21, pups from same litter were group housed in same-sex (3–4 pups/cage) and subjected to rest of the behavioral assays during the light cycle from PND28 to PND32. Western blotting and electrophysiological assessments were performed immediately after behavioral tests (Additional file 1: Fig. S1b). Three to four male offspring were randomly selected from each litter, and overall three or four litters per group were evaluated in present study to avoid litter effects.

Drug and antibodies

For prenatal VPA exposure, NaVPA was purchased from Sigma-Aldrich (St. Louis, MO), which was dissolved in 0.9% saline to obtain a concentration of 150 mg/ml at pH 7.3. For GABA_AR insertion, *N*-methyl-D-aspartate (NMDA) was purchased from Tocris (Minneapolis, MN), which was dissolved in artificial cerebrospinal fluid (aCSF) to obtain a concentration of 20 μM. For western blotting, the following antibodies of GluN2A (1:5000; Genetex; GTX63442), GluN2B (1:5000; Abcam; ab65783), GluA1 (1:5000; Abcam; ab109450), GluA2 (1:5000; Millipore; MAB397), gephyrin (1:5000; Alomone; AIP-005), GABA_AR β3 subunit (1:5000; Abcam; ab98968), and anti-β-actin antibody (1:10,000; Abcam; ab6276) were used.

Behavioral testing

All behavioral procedures were recorded using a digital video camera. Behavioral traces of rat movement during the experiments were recorded through Smart software (version 3.0; Panlab, S.L.U., Spain). The behavioral testing was performed and scored by researchers blind to the experimental conditions of the test rat.

Three-chamber social interaction test

The three-chamber social interaction test was performed based on the procedure described previously [39]. The social interaction testing apparatus was an open-topped Plexiglas box (30 × 60 × 30 cm) divided into three compartments. Among them, two identical, transparent boxes (28 × 13 × 21 cm) were respectively positioned on both side compartments. The test was composed of three

phases with different stimuli placed in each of the plastic boxes. First, during the habituation phase (5 min), no stimulus was involved. During the sociability phase (5 min), a social stimulus (stranger rat 1, S1) was enclosed in one of the transparent box in a side compartments. During the social preference phase (5 min), the stranger rat 1 (familiar, F) and a novel social stimulus (stranger rat 2, S2) were placed in each of the plastic boxes, respectively. Within each phase, test rat was introduced to the center of the apparatus and allowed for free exploration. Animals used as strangers were rats of similar age, same sex, and similar weight as the test rat. The amount of time spent in each compartment was measured. The preference index for sociability was calculated as time spent in compartment (S1 – E)/total exploration time × 100%, where E denotes the empty plastic box. The preference index for social preference was measured as time spent in compartment (S2 – F)/total exploration time × 100%.

Marble-burying test

Standard rat cages were filled with fresh bedding to a depth of 4 cm and were embedded with 20 evenly distributed marbles (~1.5 cm diameter). Rats were placed in the cage for 20 min and were allowed to explore freely. Afterward, the number of marbles that were more than two-thirds buried was counted [40].

Open-field test

The open-field test was conducted in a novel square arena (45 × 45 cm) surrounded by walls (45 cm high) made of black Plexiglas. At the start of each trial, rat was placed in the center of the apparatus and allowed to freely ambulate the apparatus for 5 min. The total distance moved and the percentage of time spent in the central 25% of the apparatus during the experiment were measured.

Elevated plus maze test

The elevated plus maze test was made of black Plexiglas and elevated at a height of 31 cm above the floor level. The plus maze contains two open arms (112 × 112 cm) and two enclosed arms (112 × 112 × 31 cm) radiating out from a central platform (10 × 10 cm). Rats were placed in the center of the maze and their movements were monitored over a 10-min period. Total time spent in the open arms of the maze was calculated and presented as a percentage of the test duration.

Forced swim test

During the forced swim test, rats were individually subjected to a 5-min swim session in a transparent Plexiglas cylinder, 60 cm high and 21 cm in diameter, filled with water (25 ± 1 °C). Immobility was defined as the absence

of active, escape-oriented behaviors, with only slight movements to keep the head above water [40].

Electrophysiology

Amygdala slices were prepared as previously described [41]. Rats were decapitated, and brains were rapidly removed and placed in ice-cold high sucrose slicing solution consisted of the following (in mM): sucrose 75, NaCl 87, KCl 2.5, CaCl₂ 0.5, MgCl₂ 4, NaHCO₃ 23, NaH₂PO₄ 1.25, and glucose 25 at pH 7.4, and equilibrated with 95% O₂–5% CO₂. Brain slices (400 μm) were then prepared through a vibrating microtome (DTK-1000; Dosaka, Kyoto, Japan) and further transferred to a holding chamber of normal aCSF, saturated with 95% O₂ and 5% CO₂ and containing the following (in mM): NaCl 130, KCl 2.5, CaCl₂ 1.2, MgCl₂ 2.4, NaHCO₃ 23, NaH₂PO₄ 1.2, and glucose 11 at pH 7.4, 30–32 °C.

During recording, an individual slice was placed in a recording chamber on an upright microscope stage (Olympus BX51W1, Tokyo, Japan) and constantly superfused at 2–5 ml/min with oxygenated aCSF at 30–32 °C. Pyramidal neurons in the basolateral amygdala (BLA) subregion of the amygdala were visualized using a NIR-sensitive CCD camera (acA2040-90 μm; Baseler). A concentric bipolar stimulating electrode (FHC, Boedoinham, ME, USA) placed outside of the BLA to stimulate the external capsule (EC) fibers from the cortex.

Whole-cell patch clamp recordings were obtained from visually identified pyramidal neurons in the BLA via a capillary glass microelectrode (4–5 MΩ). Electrode internal was composed of the following (in mM): K or Cs-gluconate 140, KCl or CsCl 10, EGTA 1, phosphocreatine 10, Mg-ATP 4, Na-GTP 0.3, and HEPES 10 at pH 7.3, 280 mOsm. For recording neuronal properties and action potentials, K-based internal solution was used, whereas for recording α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid receptors (AMPA)/NMDA receptor (NMDAR) ratio and inhibitory post-synaptic currents (IPSCs), Cs-based internal solution was used. All recordings were monitored and digitized through MultiClamp 700B and Digidata1322A, respectively. Excitatory post-synaptic currents (EPSCs) were performed in the presence of tetrodotoxin (1 μM) and picrotoxin (10 μM) in the recording aCSF. NMDAR-mediated EPSC was determined as amplitude at 50 ms after peak EPSC amplitude holding at 40 mV, whereas AMPAR-mediated EPSC was evoked as the cell voltage-clamped at –70 mV. The AMPAR/NMDAR ratio was estimated by calculating AMPAR-mediated EPSC amplitude divided by NMDAR-mediated EPSC amplitude. GABA_AR-mediated miniature IPSCs were performed with the cell held at –70 mV and the presence of 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX; 10 μM) and D-2-amino-5-phosphonovaleric

acid (D-APV; 50 μM) in the recording aCSF. The input–output curve and the reversal potential of evoked IPSCs was measured by averaging 10 recorded responses for each tested stimulation intensity and each holding potential, respectively. As described in the previous study [42], for the potentiation of GABAergic synapses, NMDA (3 min, 20 μM) was briefly applied.

Western blotting and immunoprecipitation

Whole-cell lysate preparation

The BLA subregion of the amygdala was punched from brain slices, and the tissue was then homogenized in iced-cold lysis buffer with proteinase inhibitors and phosphatase inhibitors. The prepared homogenate was centrifuged at 12,000×g for 20 min, and the supernatant was used for western blotting analysis.

Synaptoneurosomes preparation

The BLA subregion of the amygdala stimulated with NMDA or with sham solution were punched from brain slices and synaptoneurosomal fraction was prepared according to the procedure of described previously [41, 43]. The tissue was homogenized in iced-cold lysis buffer with proteinase inhibitors and phosphatase inhibitors. The mixture was loaded into a 1-ml tuberculin syringe attached to a 13 mm diameter syringe filter holder (Millipore). After filtration, the mixture was forced to pass over a three-layer nylon (Tetko, 100-μm pore diameter) rinsed with lysis buffer. The filtrate was loaded into another tuberculin syringe and forced through a pre-wetted nitrocellulose filter (5 μm, Millipore). The filtered homogenate was then centrifuged at 1000×g for 10 min, and the pellet was resuspended in lysis buffer for western blotting analysis.

Immunoprecipitation

The synaptoneurosomes were immunoprecipitated with anti-GABA_AR β3 subunit (2 μg) antibodies, or IgG in iced-cold lysis buffer overnight. The antibody-bound complex were incubated with protein G-coupled agarose beads at 4 °C for 1 h. The agarose beads were pelleted by centrifugation. After wash and elution, the immunoprecipitates were detected with anti-gephyrin antibody by western blotting analysis.

Western blotting analysis

For analysis of synaptoneurosomes, whole-cell lysates and prepared immunoprecipitates, a fixed amount of protein was subjected to western blotting. Protein concentration of prepared sample was determined by the Bio-Rad protein assay. Equal volume of 5× sample buffer (10% SDS, 250mM Tris-HCl, pH 6.8, 5% β-mercaptoethanol, 50% glycerol and 0.5% bromophenol blue) were

added to samples, and boiled for 10 min. After that, protein extracts separated on 7.5% SDS-PAGE and transferred to PVDF (Immobilon P membrane, Millipore). The membranes were blocked with 5% non-fat milk for 1 h at room temperature and incubated overnight with primary antibodies at 4 °C. Immune complexes were detected by using appropriate HRP-conjugated secondary antibodies along with ECL Plus detection reagent (PerkinElmer, Boston, MA, USA). Signals were acquired via *x*-ray films (Fujifilm Super RX). Signal intensities of proteins were determined by Image J software and were normalized to internal control for each individual sample.

Statistical analysis

All experiments are performed in a blinded manner. Statistical analyses were performed with GraphPad Prism 6. All values were expressed as the mean \pm SEM. Experiments were analyzed statistically using one-way ANOVA with Bonferroni post hoc tests or two-way repeated measure ANOVA (rmANOVA) with Bonferroni post hoc tests. Probability value (p) \leq 0.05 was considered statistically significant.

Results

Autism-like behaviors across two generations of the VPA-induced offspring

First, the three-chamber social interaction test was performed. In the sociability phase, less exploration time with stranger rat 1 ($F_{(2,33)} = 37.70$, $p < 0.0001$; Fig. 1a) and decreased preference index ($F_{(2,33)} = 45.83$, $p < 0.0001$; Fig. 1b) were observed in two generations of the VPA-induced offspring relative to the saline-exposed offspring. In the social preference phase, less exploration time with the novel stranger rat ($F_{(2,33)} = 19.77$, $p < 0.0001$; Fig. 1c) and diminished preference index ($F_{(2,33)} = 18.34$, $p < 0.0001$; Fig. 1d) were found in two generations of the VPA-induced offspring compared with the saline-exposed offspring. In the marble burying test, increased marbles buried were revealed in two generations of the VPA-induced offspring relative to the saline-exposed offspring ($F_{(2,33)} = 10.45$, $p = 0.0003$; Fig. 1e). In the open field test, no significant change in the total distance traveled among the three groups was detected ($F_{(2,33)} = 1.475$, $p = 0.2434$), while reduced time spent in the center area were found in two generations of the VPA-induced offspring compared with the saline-exposed offspring ($F_{(2,33)} = 7.592$, $p = 0.0019$; Fig. 1f). In the elevated plus-maze test, significantly decreased time spent in the open arms were shown in two generations of the VPA-induced offspring compared with the saline-exposed offspring ($F_{(2,33)} = 15.72$, $p < 0.0001$; Fig. 1g). In the forced swim test, enhanced immobility time was found in two generations of the VPA-induced offspring compared with


the saline-exposed offspring ($F_{(2,33)} = 28.54$, $p < 0.0001$; Fig. 1h). Collectively, these data support the hypothesis that maternal VPA exposure results in autism-relevant behaviors across two generations of the VPA-induced offspring.

Decreased synaptic GABA_AR levels and inhibitory transmission in two generations of the VPA-induced offspring with further reductions in the F2 generation

To address the contribution of GABAergic system to the heritable effects of maternal VPA exposure, GABA_AR expression and function were assessed. As shown in Fig. 2a, both generations of the VPA-induced offspring displayed significant reductions in the synaptic protein levels of the GABA_AR $\beta 3$ subunit in the amygdala; moreover, the reduction level was significantly greater in the F2 than the F1 generation ($F_{(2,15)} = 19.99$, $p < 0.0001$). Consistently, the input–output relationships were decreased in both generations of the VPA-induced offspring; furthermore, the level was significantly lower in the F2 compared to the F1 generation of the VPA-induced offspring (Saline vs. F1 VPA, interaction: $F_{(5,102)} = 2.585$, $p = 0.0303$; Saline vs. F2 VPA, interaction: $F_{(5,108)} = 7.825$, $p < 0.0001$; F1 VPA vs. F2 VPA, interaction: $F_{(5,102)} = 2.345$, $p = 0.0465$; Fig. 2b). No significant differences were found among the groups in the reversal potentials of IPSCs (interaction: $F_{(12,168)} = 0.3392$, $p = 0.9808$; Fig. 2c). The extent of mIPSC amplitude ($F_{(2,23)} = 17.66$, $p < 0.0001$; Fig. 2e, g) was significantly declined in the F2 generation of the VPA-induced offspring either compared with the saline-exposed offspring or the F1 generation offspring. As shown in Fig. 2f, h, both two generations of the VPA-induced offspring revealed significant reductions in the mIPSC frequency compared with the saline-exposed offspring ($F_{(2,23)} = 19.89$, $p < 0.0001$). Altogether, these data indicated diminished synaptic GABA_AR expressions and inhibitory transmission in two generations of the VPA-induced offspring with greater reductions in the F2 generation.


Loss of synaptic gephyrin levels in two generations of the VPA-induced offspring with a greater reduction in the F2 generation accompanied with weaker association of gephyrin with GABA_AR

To identify the molecular mechanism underlying the deterioration of the GABAergic system across two generations of the VPA-induced offspring, we focused on the expression profiles of a scaffold protein, gephyrin, known to play important role in the clustering and stabilization of GABA_ARs at inhibitory postsynapses [44]. Western blot analyses of synaptoneurosomal tissue showed that the expression levels of gephyrin and GABA_AR $\beta 3$ subunit were significantly decreased in



both of the F1 and F2 generations of the VPA-induced offspring compared to the saline-exposed offspring, and greater reduction levels were observed in the F2 than the F1 generation (Gephyrin: $F_{(2,21)} = 52.49$, $p < 0.0001$; GABA_A $\beta 3$ subunit: $F_{(2,18)} = 21.4$, $p < 0.0001$; Fig. 3a, b). No significant difference was found in gephyrin and GABA_A $\beta 3$ subunit levels among the three groups in the whole-cell fraction from the amygdala (Gephyrin: $F_{(2,15)} = 1.022$, $p = 0.3837$;

GABA_A $\beta 3$ subunit: $F_{(2,15)} = 1.609$, $p = 0.2328$; Fig. 3c, d). In immunoprecipitation experiments, the association of the GABA_A $\beta 3$ subunit and gephyrin was significantly attenuated in both F1 and F2 generations of the VPA-induced offspring compared to the saline-exposed offspring, and greater loss were measured in the F2 than the F1 generation of the VPA-induced offspring ($F_{(2,15)} = 23.01$, $p < 0.0001$; Fig. 3e). In summary, these data indicated declined gephyrin and GABA_A $\beta 3$



levels, and their association in two generations of the VPA-induced offspring with further reductions in the F2 generation, suggesting that clustering of gephyrin and GABA_AR at the synapses is dysregulated in both generations of the VPA-induced offspring with deterioration in the F2 generation.

Defective NMDA-induced gephyrin and GABA_AR enhancements in two generations of the VPA-induced offspring with difference between two generations

To further investigate the impact of losing synaptic gephyrin and GABA_AR on inhibitory synapses in two generations of the VPA-induced offspring, we evoked





Fig. 3 Synaptic gephyrin levels and gephyrin-GABA_AR associations in two generations of the VPA-induced offspring. **a, b** Representative western blot profile and the protein levels of gephyrin (**a**) and GABA_AR β3 subunit (**b**) in synaptoneurosomes from the amygdala. Gephyrin, *n* = 8 rats from three or four litters for each condition; GABA_AR β3 subunit, *n* = 7 rats from three or four litters for each condition. **c, d** Representative western blot profile and the protein levels of gephyrin (**c**) and GABA_AR β3 subunit (**d**) in whole-cell lysate from the amygdala. Gephyrin, *n* = 6 rats from three or four litters for each condition; GABA_AR β3 subunit, *n* = 6 rats from three or four litters for each condition. **(e)** Representative western blot profile and the protein levels of co-immunoprecipitation of gephyrin and GABA_AR β3 subunit in synaptoneurosomes from the amygdala. *n* = 6 rats from three or four litters for each condition. Data are presented as mean ± SEM; **p* < 0.05, ***p* < 0.01, ****p* < 0.001 vs. indicated control; one-way ANOVA with Bonferroni post-hoc

the potentiation of inhibitory synapses accompanied with clustering of gephyrin and GABA_AR at the synapses by a brief application of NMDA (3 min, 20 μM) [42]. Two-way ANOVA followed by Bonferroni's post hoc test revealed that NMDA induced significant enhancements of gephyrin (*p* < 0.01) and GABA_AR β3 subunit (*p* < 0.001) levels in the synaptoneurosomal fraction from the amygdala of the saline-exposed offspring, but not in both of the F1 and F2 generations of the VPA-induced offspring. Moreover, significant effects of generation and NMDA treatment, and significant interaction between generation and treatment were found on synaptic levels of gephyrin and GABA_AR β3 subunit (gephyrin: generation effect, $F_{(2,36)} = 83.93$, *p* < 0.0001; treatment effect, $F_{(1,36)} = 16.23$, *p* = 0.0003; interaction, $F_{(2,36)} = 3.637$, *p* = 0.0364. GABA_AR β3 subunit: generation effect, $F_{(2,48)} = 61.96$, *p* < 0.0001; treatment effect, $F_{(1,48)} = 9.658$, *p* = 0.0032; interaction,


$F_{(2,48)} = 6.636$, *p* = 0.0029; Fig. 4a–d). Likewise, two-way ANOVA followed by Bonferroni's post hoc test revealed an increase in mIPSC amplitude (*p* < 0.001) but not frequency after NMDA application in saline-exposed offspring, whereas no significant difference were measured in both generations of the VPA-induced offspring. Furthermore, significant effects of generation and NMDA treatment, and significant interaction between generation and treatment were found on mIPSC amplitude rather than frequency (mIPSC amplitude: generation effect, $F_{(2,50)} = 100.7$, *p* < 0.0001; treatment effect, $F_{(1,50)} = 10.29$, *p* = 0.0023; interaction, $F_{(2,50)} = 14.56$, *p* < 0.0001. mIPSC frequency: generation effect, $F_{(2,50)} = 48.36$, *p* < 0.0001; treatment effect, $F_{(1,50)} = 0.1254$, *p* = 0.7248; interaction, $F_{(2,50)} = 0.09772$, *p* = 0.9071; Fig. 4e–k). Collectively, these data revealed that NMDA-induced gephyrin and



GABA_AR enhancements at the synapses was defective in two generations of the VPA-induced offspring; moreover, the significant generation effects suggest differential GABAergic potentiation in response to NMDA treatment between generations.

Enhanced glutamatergic modifications across generations of the VPA-induced offspring

In addition to the dampened inhibitory tone observed in the present study, we also examined the alterations in the excitatory glutamatergic system in the VPA model. To



accomplish this, we measured the expression profile and synaptic transmission performed by ionotropic glutamate receptors, NMDARs and AMPARs across two generations of the VPA-induced offspring. We observed that the protein levels of GluN2A, GluN2B, and GluA1, but not GluA2 subunits, were significantly increased in synaptoneurosomal tissue from the amygdala of both generations of the VPA-induced offspring (GluN2A: $F_{(2,15)} = 9.446$, $p = 0.0022$; GluN2B: $F_{(2,15)} = 8.312$, $p = 0.0037$; GluA1: $F_{(2,15)} = 7.532$, $p = 0.0054$; GluA2: $F_{(2,12)} = 0.2646$, $p = 0.7719$; Fig. 5a–d). The whole-cell patch clamp measurements revealed that the input–output curves of NMDAR-EPSC were significantly enhanced in the amygdala of both generations of the VPA-induced offspring, and no significant difference was found between the F1 and F2 generations of the VPA-induced offspring (Saline vs. F1 VPA, interaction: $F_{(10,96)} = 2.241$, $p = 0.0214$; Saline vs. F2 VPA, interaction: $F_{(5,66)} = 2.528$, $p = 0.0373$; F1 VPA vs. F2 VPA, interaction: $F_{(5,66)} = 0.4218$, $p = 0.8319$; Fig. 5e). Likewise, the input-output relationships of

AMPA-EPSC were significantly elevated in both generations of the VPA-induced offspring, and no significant difference was found between the F1 and F2 generations of the VPA-induced offspring (Saline vs. F1 VPA, interaction: $F_{(5,60)} = 4.065$, $p = 0.0030$; Saline vs. F2 VPA, interaction: $F_{(5,66)} = 2.758$, $p = 0.0253$; F1 VPA vs. F2 VPA, interaction: $F_{(5,66)} = 0.2272$, $p = 0.9495$; Fig. 5f). The AMPAR/NMDAR ratio remained unchanged in the amygdala of both generations of the VPA-induced offspring compared with the saline-exposed offspring ($F_{(2,25)} = 0.7145$, $p = 0.4992$; Fig. 5g). These results indicated enhanced expression and function of ionotropic glutamate receptors in the amygdala of both F1 and F2 generations of the VPA-induced offspring without difference.

Discussion

In this study, we provide novel evidence about the E/I synaptic impairments in the amygdala from two generations of the VPA-induced offspring. Importantly, we

characterize the GABAergic deteriorations across generations of the VPA model, which specifically, include the greater reductions in GABA_AR and gephyrin levels, and the loss of GABA_AR-gephyrin interaction compounding with defective NMDA-induced enhancements of gephyrin and GABA_AR at the synapses in the F2 generation. These results suggest a potential therapeutic role of GABAergic system in the generational pathophysiology of ASD.

The VPA model is a widely used animal model of ASD owing to its clinical relevance, for a 7–10 fold increased relative risk for ASD [45, 46], and validity [47], for similar behavioral and physiological features with patients. Other than genetic models, the VPA model provides a global aspect of idiopathic ASD, with both environmental and epigenetic origins contributing to 85–95% of ASD cases [48]. Furthermore, the histone deacetylase (HDAC) inhibitory role of VPA may offer a straightforward way to identify epigenetic patterns across ASD generations. These aspects suggest that the VPA model is a valid tool with its unique advantage of studying the cross-generational effects of ASD. The present and previous studies have shown that behavioral and cerebellar abnormalities of the F1 generation in VPA-exposed offspring were transferred to the F2 or F3 generations [31, 49]. This is consistent with previous research revealing that environmental exposure influences not only the exposed individual, but also future generations [10, 50–55]. The proposed mechanism underlying these cross-generational effects is that epigenetic modifications in parental somatic and germ cells may be imprinted onto the offspring [56]. Recent human and animal studies have discovered various mechanisms underlying epigenetic inheritance of neurodevelopmental disorders, such as DNA methylation, histone modifications, and small non-coding RNAs [57, 58]. Alterations in the transcriptome profiles from different generations with neurodevelopmental disorders have been implicated as the consequence of cross-generational epigenetic regulation [13, 30]. Accordingly, it is reasonable to conclude that epigenetic regulation is implicated in the cross-generational effects observed in the VPA-induced ASD model of the present study.

Transient histone hyperacetylation following VPA exposure has been found in the embryonic brain of offspring with ASD [59], further leading to alterations in downstream ASD-related genes [47, 60]. Suppression of genes responsible for the development of GABAergic neurons was found through HDAC inhibition by VPA [61–63]. These findings suggest that the HDAC inhibitory function of VPA may contribute to the decreased GABAergic function in ASD offspring. Dysregulation of GABA_AR-mediated neuronal inhibition is widely considered as the major etiology of a variety

of neurodevelopmental disorders [32, 64]. Clinically, approximately 20–35% reductions in surface GABA_AR expressions were found in critical brain regions of patients with ASD [28]. In addition, modifications of the GABA_AR β 3 subunit have been emphasized for their direct contribution to the pathophysiology of animal models of ASD [36, 37]. In line with the implications of GABA_AR dysregulations in ASD patients and animals, the present study provides first demonstration about the reductions in synaptic GABA_AR β 3 subunit levels and GABAergic transmission from the F1 generation up to the F2 generation in ASD offspring induced by prenatal VPA exposure. These observations suggest GABAergic modulations as a general pathogenic mechanism across generations of animal model of ASD.

One of the most critical findings in the present study is the reductions of synaptic GABA_AR levels and the amplitude of mIPSCs in two generations of the VPA-induced offspring with deteriorations in the F2 generation than the F1 generation. These findings indicate decreased GABAergic postsynaptic function across two generations of the VPA-induced offspring, and the dysfunctions is worsened in the F2 generation. In contrast, the present and previous studies revealed similar reductions of mIPSC frequency and inhibitory presynaptic marker expression [31] in both the F1 and F2 generations of VPA-induced offspring. These observations show that GABAergic deterioration in the F2 generation of our ASD model specifically occurs in the postsynaptic region, rather than in the presynaptic region.

Considering the principal role of gephyrin in stabilizing of GABA_AR at the synaptic region [65], we found that the synaptic levels of gephyrin were eliminated in two generations of the VPA-induced offspring. There is lower gephyrin expression in the F2 generation than in the F1 generation. That is, the expression profile of synaptic gephyrin is parallel to synaptic GABA_AR in two generations of individuals with ASD. Moreover, our results further demonstrated a greater loss of gephyrin and GABA_AR association in the F2 generation than in the F1 generation. This suggests a novel physiological role for gephyrin-associated GABA_AR β 3 subunit in the cross-generational effects of ASD pathophysiology under VPA exposure. Together with previous mechanistic understandings [66–68], our present identification of the gephyrin involvement in synaptic GABA_AR destabilization and the reduced amplitude of mIPSCs in the F2 generation of our ASD model supporting a great impact of dysregulated gephyrin on the altered postsynaptic GABA_AR levels in cross-generational ASD pathophysiology.

In the present study, briefly applying NMDA enhances of both GABA_AR and gephyrin in the postsynaptic

region. Besides, NMDA treatment could also trigger AMPAR internalization at the excitatory synapses resulting in the depression of glutamatergic synapses [69]. Aberrant NMDA-induced AMPAR endocytosis in the VPA-induced ASD animals has been found in our previous study [41]. Together with these evidence, the impairments of both GABA_AR exocytosis and AMPAR endocytosis triggered via the moderate NMDAR activation protocol were well-demonstrated in the present ASD model. On the other hand, phosphorylation of target proteins, including the GABA_AR $\beta 3$ subunit, via Ca²⁺/calmodulin protein kinase II (CaMKII) after applying NMDA stimulates the rapid insertion of GABA_AR at the cell surface with enhanced GABAergic currents [42, 69–71]. Accordingly, we potentiated synaptic GABA_AR expression and transmission, accompanied by increased gephyrin levels in the control group after NMDA treatment. In contrast, aberrant responses to NMDA treatment were found in the GABAergic synapses of two generations of VPA-induced offspring, with significant generational effects. These results indicate a differential GABA_AR insertion triggered by NMDA across generations of the present ASD animals. Even though GABA_AR trafficking into the cell surface is the proposed mechanism, we still cannot rule out the possible enhancements of gephyrin and GABA_AR association under NMDA treatment from our and other findings. Increased gephyrin levels at the synapses are present alongside increased GABA_AR levels. Enhanced GABAergic transmission was also identified following NMDA treatment in our and other studies [42]. Moreover, manipulation of gephyrin by gene knockout, antisense approaches, and identification of post-translational modifications at specific gephyrin residues highlight the critical role of gephyrin in synaptic GABA_AR clustering [72–75]. These findings suggest that not only the insertion of GABA_AR, but also enhancement of gephyrin and GABA_AR association contributes to the NMDA-enhanced effects on GABAergic synapses. The present findings in either the gephyrin-associated GABA_AR $\beta 3$ subunit, or the NMDA-induced effects on GABAergic synapses is sufficient to explain the dependence of gephyrin on GABAergic deteriorations at the postsynaptic region across generations of VPA-induced animals with ASD. The functional interplay of gephyrin with synaptic proteins, such as neurexins and neuroligins, implicated in neurodevelopmental diseases has long been discovered [76, 77]. Copy number variations and exonic deletions in the *GPHN* gene have been identified in individuals with ASD [78, 79], uncovering strong human genetic evidence for the involvement of gephyrin in the pathogenesis of ASD. The present study uncovered a previously unknown pathogenic role of gephyrin compromised in the generational effects on GABA_AR

expression and function among the pathophysiology of ASD.

A strong linkage between glutamatergic dysfunctions in the brain and behavioral abnormalities in the ASD animals was well-identified in previous studies [20, 21, 80, 81]. We revealed the enhancements of NMDAR and AMPAR expressions and currents in the amygdala from both F1 and F2 generations of the VPA-induced offspring. Increased synaptic levels of GluN2A, GluN2B, and GluA1, rather than GluA2, were observed. This is consistent with previous findings that GluA2-containing AMPAR endocytosis is abnormal in the VPA-exposed offspring, and the baseline synaptic GluA2 levels remain unchanged [41]. While the AMPAR/NMDAR ratio is a strong index of the synaptic state, particularly contributed by postsynaptic AMPARs and NMDARs, no significant difference was found in the two generations of VPA-induced offspring. Together with previous findings [20, 82], one possible explanation may be the similar enhancement of both NMDAR- and AMPAR-mediated currents in the VPA-induced offspring. Previous research showed a significantly altered rectification of AMPAR-mediated currents with an unaltered AMPAR/NMDAR ratio [83], suggesting further examinations to elucidate the detailed contributions of each subunit. In a brief summary, these findings suggest that the contribution of glutamatergic tone cannot be ruled out in the cross-generational effects of ASD. More importantly, through the discovery of deteriorations in GABAergic system rather than in glutamatergic system in the F2 generation than the F1 generation of the ASD offspring, great attentions on the role of GABAergic modulation in the cross-generational effects of ASD pathogenesis must be paid.

In the present study, increased glutamatergic receptor expressions and functions, and declined GABAergic receptor expressions and functions at the synaptic levels were demonstrated in the amygdala from two generations of the VPA-induced offspring. In consistency, a prior study on the prefrontal cortex (PFC) illustrated enhanced glutamate-related proteins and reduced GABA-related proteins up to the F2 generation of the VPA-exposed offspring [31]. Given the central role of both the amygdala and PFC in social/emotional brain circuits [20, 84, 85], these observations support E/I imbalance as the hallmark feature in the cross-generational effects of ASD causing ASD-like behavioral phenotypes in the subsequent generations.

In addition to the present findings on the cross-generational effects of VPA-induced ASD in animals, a study on human recently reported the adverse neurodevelopmental outcomes of VPA, including malformations and neurodevelopmental disorders, diagnosed from about 53% of F2 generations [86]. Clinical studies have

recently suggested that multigenerational risks increase the prevalence of ASD under accumulated epigenetic alterations reflecting past environmental exposure levels and life history [87–90]. Previous evidence has shown differing or worsening behavioral performance in the F2 generation than in the F1 generation, with different transcriptomic changes in models exposed to environmental insults [10, 13]. This indicates that accumulation of epigenetic modifications may induce different pathological conditions across generations of ASD. The present demonstration of profound GABAergic phenotypes in the F2 generation compared to the F1 generation of the VPA model further provides a novel biomarker for the multigenerational effects of ASD. In support of this, a preclinical study showed the beneficial effects of prenatal GABA_BR agonist treatment on the F2 generation of the VPA model [91]. These findings suggest that dysfunction in GABAergic system is a critical pathological mechanism that provides an important direction for the therapeutic strategy of cross-generational effects on ASD.

Conclusions

The present study is the first supportive demonstration of E/I disturbances as the central hypothesis in the cross-generational pathogenesis of F2 generation of the ASD animals. More intriguingly, significant deteriorations were found in the GABAergic system rather than the glutamatergic system of the F2 generation than the F1 generation providing novel perspectives on the cross-generational effects of ASD pathophysiology on inhibitory synaptic dysfunctions. Mechanistically, our findings on either GABA_AR-gephyrin interaction at the synaptic level or NMDA-induced enhancements of gephyrin and GABA_AR offer valuable insight into the novel regulatory role of gephyrin in both GABA_AR expression and function across generations of the ASD offspring. Overall, these observations suggest that targeting the GABAergic system may be a viable therapeutic approach toward correcting the generational pathophysiology of ASD which is also predictive for neurodevelopmental disorders with at-risk early-life experience, or parental transmission into subsequent generations.

Abbreviations

AMPA: α -Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor; ASD: Autism spectrum disorder; BLA: Basolateral amygdala; E: Embryonic day; E/I: Excitatory/inhibitory; EPSC: Excitatory postsynaptic potential; GABA_AR: γ -Aminobutyric acid type A receptor; GluA1: AMPAR receptor subunit type 1; GluA2: AMPAR receptor subunit type 2; mIPSC: Miniature inhibitory postsynaptic current; NMDAR: *N*-methyl-D-aspartate receptor; GluN2A: NMDA receptor subunit 2 A; GluN2B: NMDA receptor subunit 2B; PND: Postnatal day; VPA: Valproate.

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s12929-022-00835-w>.

Additional file 1: Figure S1. Experimental design for measuring the autism-like phenotypes across two generations of the VPA-induced offspring. (a) Strategies of producing the F1 and F2 generations of the VPA-induced offspring. (b) Timeline of experimental procedures. Five-day behavioral assays were conducted from PND28 to PND32, including three-chamber social test (PND28), open field test (PND29), elevated plus maze test (PND30), marble burying test (PND31) and forced swim test (PND32). Western blotting and electrophysiological recordings were performed soon after the behavioral assays. E, embryonic day; PND, postnatal day

Acknowledgements

The authors would like to thank Editage for editing the English in this manuscript.

Author contributions

HCL and PSC conceived and designed the experiments. MCC, HFW, CWL, YJC, HC performed the experiments. MCC and HFW analyzed the data. MCC and HCL wrote the manuscript. All authors read and approved the final manuscript.

Funding

This study was supported by Grants from the Ministry of Science and Technology (Grant numbers: MOST 111-2320-B-A49-008, MOST 111-2811-B-A49A-004, MOST 110-2320-B-A49A-503, MOST 110-2628-B-A49A-504, MOST 109-2628-B-010-003, MOST 108-2628-B-010-004, MOST 107-2811-B-010-519); "Yin Yen-Liang Foundation Development and Construction Plan" of the College of Medicine, National Yang Ming Chiao Tung University; the National Yang Ming Chiao Tung University-Far Eastern Memorial Hospital Joint Research Program, Taiwan (Grant number: #NYMU-FEMH 110DN12) and the Brain Research Center, National Yang Ming Chiao Tung University from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan (Grant numbers: 108BRC-B503; 109BRC-B503; 110BRC-B503; 111W32503); the Kaohsiung Medical University-National Yang Ming Chiao Tung University Joint Research Program, Taiwan (Grant number: NYCUKMU-111-I008).

Availability of data and materials

All data generated or analysed during this study are included in this published article.

Declarations

Ethics approval and consent to participate

All experimental procedures complied with the National Institute of Health Guide for the Care and Use of Laboratory Animals (USA) and approved by the Institutional Animal Care and Use Committee at National Yang Ming Chiao Tung University with a Project number 1091206n.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

¹Department and Institute of Physiology, School of Medicine, National Yang Ming Chiao Tung University, Tainan 112, Taiwan. ²Ph.D. Program for Neural Regenerative Medicine, College of Medical Science and Technology, Taipei Medical University and National Health Research Institutes, Taipei 110, Taiwan. ³Department of Psychiatry, Institute of Behavioral Medicine, College of Medicine and Hospital, National Cheng Kung University Hospital, National Cheng Kung University, No. 138, Sheng-Li Road, Tainan 704, Taiwan. ⁴Institute of Behavioral Medicine, College of Medicine, National Cheng Kung University,

Tainan 704, Taiwan. ⁵Brain Research Center, National Yang Ming Chiao Tung University, Taipei 112, Taiwan.

Received: 1 April 2022 Accepted: 6 July 2022

Published online: 11 July 2022

References

- Baio J, Wiggins L, Christensen D, Maenner M, Daniels J, Warren Z, et al. Prevalence of autism spectrum disorder among children aged 8 years—autism and developmental disabilities monitoring network, 11 sites, United States, 2014. *MMWR Surveill Summ*. 2018;67(6):1–23.
- Landrigan PJ, Lambertini L, Birnbaum LS. A research strategy to discover the environmental causes of autism and neurodevelopmental disabilities. *Environ Health Perspect*. 2012;120(7):a258–60.
- Toth M. Mechanisms of non-genetic inheritance and psychiatric disorders. *Neuropsychopharmacology*. 2015;40(1):129–40.
- Rodgers AB, Morgan CP, Leu NA, Bale TL. Transgenerational epigenetic programming via sperm microRNA recapitulates effects of paternal stress. *Proc Natl Acad Sci USA*. 2015;112(44):13699–704.
- Haugen AC, Schug TT, Collman G, Heindel JJ. Evolution of DOHaD: the impact of environmental health sciences. *J Dev Orig Health Dis*. 2015;6(2):55–64.
- Meyer U. Neurodevelopmental resilience and susceptibility to maternal immune activation. *Trends Neurosci*. 2019;42(11):793–806.
- Zhou Y, Zhang M, Liu W, Li Y, Qin Y, Xu Y. Transgenerational transmission of neurodevelopmental disorders induced by maternal exposure to PM2.5. *Chemosphere*. 2020;255:126920.
- Kioumourtzoglou MA, Coull BA, O'Reilly EJ, Ascherio A, Weisskopf MG. Association of exposure to diethylstilbestrol during pregnancy with multigenerational neurodevelopmental deficits. *JAMA Pediatr*. 2018;172(7):670–7.
- Quinn KM, Doyle TJ, Kim KH, Rissman EF. Transgenerational effects of di-(2-ethylhexyl) phthalate (DEHP) on stress hormones and behavior. *Endocrinology*. 2015;156(9):3077–83.
- Weber-Stadlbauer U, Richetto J, Zwamborn RAJ, Sliker RC, Meyer U. Transgenerational modification of dopaminergic dysfunctions induced by maternal immune activation. *Neuropsychopharmacology*. 2021;46(2):404–12.
- Angelidou A, Asadi S, Alysandratos KD, Karagkouni A, Kourembanas S, Theoharides TC. Perinatal stress, brain inflammation and risk of autism—review and proposal. *BMC Pediatr*. 2012;12:89.
- Class QA, Abel KM, Khashan AS, Rickert ME, Dalman C, Larsson H, et al. Offspring psychopathology following preconception, prenatal and postnatal maternal bereavement stress. *Psychol Med*. 2014;44(1):71–84.
- Manners MT, Yohn NL, Lahens NF, Grant GR, Bartolomei MS, Blendy JA. Transgenerational inheritance of chronic adolescent stress: effects of stress response and the amygdala transcriptome. *Genes Brain Behav*. 2019;18(7):e12493.
- Qiu A, Anh TT, Li Y, Chen H, Rifkin-Graboi A, Broekman BF, et al. Prenatal maternal depression alters amygdala functional connectivity in 6-month-old infants. *Transl Psychiatry*. 2015;5(2):e508.
- Kemp JVA, Bernier E, Lebel C, Kopala-Sibley DC. Associations between parental mood and anxiety psychopathology and offspring brain structure: a scoping review. *Clin Child Fam Psychol Rev*. 2022;25(1):222–47.
- Avino TA, Barger N, Vargas MV, Carlson EL, Amaral DG, Bauman MD, et al. Neuron numbers increase in the human amygdala from birth to adulthood, but not in autism. *Proc Natl Acad Sci USA*. 2018;115(14):3710–5.
- Shen MD, Li DD, Keown CL, Lee A, Johnson RT, Angkustsiri K, et al. Functional connectivity of the amygdala is disrupted in preschool-aged children with autism spectrum disorder. *J Am Acad Child Adolesc Psychiatry*. 2016;55(9):817–24.
- Rojas DC, Smith JA, Benkers TL, Camou SL, Reite ML, Rogers SJ. Hippocampus and amygdala volumes in parents of children with autistic disorder. *Am J Psychiatry*. 2004;161(11):2038–44.
- Schumann CM, Amaral DG. Stereological analysis of amygdala neuron number in autism. *J Neurosci*. 2006;26(29):7674–9.
- Lin HC, Gean PW, Wang CC, Chan YH, Chen PS. The amygdala excitatory/inhibitory balance in a valproate-induced rat autism model. *PLoS ONE*. 2013;8(1):e55248.
- Markram K, Rinaldi T, La Mendola D, Sandi C, Markram H. Abnormal fear conditioning and amygdala processing in an animal model of autism. *Neuropsychopharmacology*. 2008;33(4):901–12.
- Rubenstein JL, Merzenich MM. Model of autism: increased ratio of excitation/inhibition in key neural systems. *Genes Brain Behav*. 2003;2:255–67.
- Phillips M, Pozzo-Miller L. Dendritic spine dysgenesis in autism related disorders. *Neurosci Lett*. 2015;601:30–40.
- Hutsler JJ, Zhang H. Increased dendritic spine densities on cortical projection neurons in autism spectrum disorders. *Brain Res*. 2010;1309:83–94.
- Fatemi SH, Reutiman TJ, Folsom TD, Rustan OG, Rooney RJ, Thuras PD. Downregulation of GABAA receptor protein subunits alpha6, beta2, delta, epsilon, gamma2, theta, and rho2 in superior frontal cortex of subjects with autism. *J Autism Dev Disord*. 2014;44(8):1833–45.
- Purcell AE, Jeon OH, Zimmerman AW, Blue ME, Pevsner J. Postmortem brain abnormalities of the glutamate neurotransmitter system in autism. *Neurology*. 2001;57(9):1618–28.
- Fatemi SH, Reutiman TJ, Folsom TD, Thuras PD. GABA(A) receptor downregulation in brains of subjects with autism. *J Autism Dev Disord*. 2009;39(2):223–30.
- Oblak AL, Gibbs TT, Blatt GJ. Reduced GABAA receptors and benzodiazepine binding sites in the posterior cingulate cortex and fusiform gyrus in autism. *Brain Res*. 2011;1380:218–28.
- Guang S, Pang N, Deng X, Yang L, He F, Wu L, et al. Synaptopathology involved in autism spectrum disorder. *Front Cell Neurosci*. 2018;12:470.
- Weber-Stadlbauer U, Richetto J, Labouesse MA, Bohacek J, Mansuy IM, Meyer U. Transgenerational transmission and modification of pathological traits induced by prenatal immune activation. *Mol Psychiatry*. 2017;22(1):102–12.
- Choi CS, Gonzales EL, Kim KC, Yang SM, Kim JW, Mabung DF, et al. The transgenerational inheritance of autism-like phenotypes in mice exposed to valproic acid during pregnancy. *Sci Rep*. 2016;6:36250.
- Ramamoorthi K, Lin Y. The contribution of GABAergic dysfunction to neurodevelopmental disorders. *Trends Mol Med*. 2011;17(8):452–62.
- Hogart A, Wu D, LaSalle JM, Schanen NC. The comorbidity of autism with the genomic disorders of chromosome 15q11.2-q13. *Neurobiol Dis*. 2010;38(2):181–91.
- Samaco R, Hogart A, LaSalle J. Epigenetic overlap in autism-spectrum neurodevelopmental disorders: MECP2 deficiency causes reduced expression of UBE3A and GABRB3. *Hum Mol Genet*. 2005;14(4):483–92.
- Delahanty RJ, Kang JQ, Brune CW, Kistner EO, Courchesne E, Cox NJ, et al. Maternal transmission of a rare GABRB3 signal peptide variant is associated with autism. *Mol Psychiatry*. 2011;16(1):86–96.
- Nakatani J, Tamada K, Hatanaka F, Ise S, Ohta H, Inoue K, et al. Abnormal behavior in a chromosome-engineered mouse model for human 15q11-13 duplication seen in autism. *Cell*. 2009;137(7):1235–46.
- Vien TN, Modgil A, Abramian AM, Jurd R, Walker J, Brandon NJ, et al. Compromising the phosphodependent regulation of the GABAAR beta3 subunit reproduces the core phenotypes of autism spectrum disorders. *Proc Natl Acad Sci USA*. 2015;112(48):14805–10.
- DeLorey TM, Sahbaie P, Hashemi E, Homanics GE, Clark JD. Gabrb3 gene deficient mice exhibit impaired social and exploratory behaviors, deficits in non-selective attention and hypoplasia of cerebellar vermal lobules: a potential model of autism spectrum disorder. *Behav Brain Res*. 2008;187(2):207–20.
- Wu HF, Chen YJ, Chu MC, Hsu YT, Lu TY, Chen IT, et al. Deep brain stimulation modified autism-like deficits via the serotonin system in a valproic acid-induced rat model. *Int J Mol Sci*. 2018;19(9):2840.
- Wu HF, Lu TY, Chu MC, Chen PS, Lee CW, Lin HC. Targeting the inhibition of fatty acid amide hydrolase ameliorates the endocannabinoid-mediated synaptic dysfunction in a valproic acid-induced rat model of Autism. *Neuropharmacology*. 2019;162:107736.
- Wu HF, Chen PS, Hsu YT, Lee CW, Wang TF, Chen YJ, et al. D-Cycloserine ameliorates autism-like deficits by removing GluA2-containing AMPA receptors in a valproic acid-induced rat model. *Mol Neurobiol*. 2018;55(6):4811–24.
- Petrini EM, Ravasenga T, Hausrat TJ, Iurilli G, Olcese U, Racine V, et al. Synaptic recruitment of gephyrin regulates surface GABAA receptor dynamics for the expression of inhibitory LTP. *Nat Commun*. 2014;5:3921.
- Johnson M, Chotiner J, Watson J. Isolation and characterization of synaptoneuroosomes from single rat hippocampal slices. *J Neurosci Methods*. 1997;77(2):151–6.

44. Fritschy JM, Harvey RJ, Schwarz G. Gephyrin: where do we stand, where do we go? *Trends Neurosci.* 2008;31(5):257–64.
45. Christensen J, Gronborg TK, Sorensen MJ, Schendel D, Parner ET, Pedersen LH, et al. Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. *JAMA.* 2013;309(16):1696–703.
46. Ornoy A, Weinstein-Fudim L, Ergaz Z. Prenatal factors associated with autism spectrum disorder (ASD). *Reprod Toxicol.* 2015;56:155–69.
47. Mabunga DF, Gonzales EL, Kim JW, Kim KC, Shin CY. Exploring the validity of valproic acid animal model of autism. *Exp Neurobiol.* 2015;24(4):285–300.
48. Casanova MF, Casanova EL, Frye RE, Baeza-Velasco C, LaSalle JM, Hagerman RJ, et al. Editorial: Secondary vs. idiopathic autism. *Front Psychiatry.* 2020;11:297.
49. Tartaglione AM, Cipriani C, Chiarotti F, Perrone B, Balestrieri E, Matteucci C, et al. Early behavioral alterations and increased expression of endogenous retroviruses are inherited across generations in mice prenatally exposed to valproic acid. *Mol Neurobiol.* 2019;56(5):3736–50.
50. Garrido N, Cruz F, Egea RR, Simon C, Sadler-Riggleman I, Beck D, et al. Sperm DNA methylation epimutation biomarker for paternal offspring autism susceptibility. *Clin Epigenet.* 2021;13(1):6.
51. Kleeman EA, Gubert C, Hannan AJ. Transgenerational epigenetic impacts of parental infection on offspring health and disease susceptibility. *Trends Genet.* 2022;38:662–75.
52. Ben Maamar M, Beck D, Nilsson E, McCarrey JR, Skinner MK. Developmental origins of transgenerational sperm histone retention following ancestral exposures. *Dev Biol.* 2020;465(1):31–45.
53. Klengel T, Binder EB. Epigenetics of stress-related psychiatric disorders and gene \times environment interactions. *Neuron.* 2015;86(6):1343–57.
54. Vickers MH. Early life nutrition, epigenetics and programming of later life disease. *Nutrients.* 2014;6(6):2165–78.
55. Bodden C, Hannan AJ, Reichelt AC. Diet-induced modification of the sperm epigenome programs metabolism and behavior. *Trends Endocrinol Metab.* 2020;31(2):131–49.
56. Breton CV, Landon R, Kahn LG, Enlow MB, Peterson AK, Bastain T, et al. Exploring the evidence for epigenetic regulation of environmental influences on child health across generations. *Commun Biol.* 2021;4(1):769.
57. Xavier MJ, Roman SD, Aitken RJ, Nixon B. Transgenerational inheritance: how impacts to the epigenetic and genetic information of parents affect offspring health. *Hum Reprod Update.* 2019;25(5):518–40.
58. Perez MF, Lehner B. Intergenerational and transgenerational epigenetic inheritance in animals. *Nat Cell Biol.* 2019;21(2):143–51.
59. Kataoka S, Takuma K, Hara Y, Maeda Y, Ago Y, Matsuda T. Autism-like behaviours with transient histone hyperacetylation in mice treated prenatally with valproic acid. *Int J Neuropsychopharmacol.* 2013;16(1):91–103.
60. Kim KC, Lee DK, Go HS, Kim P, Choi CS, Kim JW, et al. Pax6-dependent cortical glutamatergic neuronal differentiation regulates autism-like behavior in prenatally valproic acid-exposed rat offspring. *Mol Neurobiol.* 2014;49(1):512–28.
61. Wang CC, Chen PS, Hsu CW, Wu SJ, Lin CT, Gean PW. Valproic acid mediates the synaptic excitatory/inhibitory balance through astrocytes—a preliminary study. *Prog Neuro-psychopharmacol Biol Psychiatry.* 2012;37(1):111–20.
62. Kumamaru E, Egashira Y, Takenaka R, Takamori S. Valproic acid selectively suppresses the formation of inhibitory synapses in cultured cortical neurons. *Neurosci Lett.* 2014;569:142–7.
63. Meganathan K, Jagtap S, Srinivasan SP, Wagh V, Hescheler J, Hengstler J, et al. Neuronal developmental gene and miRNA signatures induced by histone deacetylase inhibitors in human embryonic stem cells. *Cell Death Dis.* 2015;6(5):e1756.
64. Chattopadhyaya B, Cristo GD. GABAergic circuit dysfunctions in neurodevelopmental disorders. *Front Psychiatry.* 2012;3:51.
65. Pizzarelli R, Griguoli M, Zacchi P, Petrini EM, Barberis A, Cattaneo A, et al. Tuning GABAergic inhibition: gephyrin molecular organization and functions. *Neuroscience.* 2020;439:125–36.
66. Kowalczyk S, Winkelmann A, Smolinsky B, Forstera B, Neundorff I, Schwarz G, et al. Direct binding of GABAA receptor beta2 and beta3 subunits to gephyrin. *Eur J Neurosci.* 2013;37(4):544–54.
67. Groeneweg FL, Trattinig C, Kuhse J, Nawrotzki RA, Kirsch J. Gephyrin: a key regulatory protein of inhibitory synapses and beyond. *Histochem Cell Biol.* 2018;150(5):489–508.
68. Kirsch J, Kuhse J, Betz H. Targeting of glycine receptor subunits to gephyrin-rich domains in transfected human embryonic kidney cells. *Mol Cell Neurosci.* 1995;6(5):450–61.
69. Marsden KC, Beattie JB, Friedenthal J, Carroll RC. NMDA receptor activation potentiates inhibitory transmission through GABA receptor-associated protein-dependent exocytosis of GABA(A) receptors. *J Neurosci.* 2007;27(52):14326–37.
70. Saliba RS, Kretschmannova K, Moss SJ. Activity-dependent phosphorylation of GABAA receptors regulates receptor insertion and tonic current. *EMBO J.* 2012;31(13):2937–51.
71. Luscher B, Fuchs T, Kilpatrick CL. GABAA receptor trafficking-mediated plasticity of inhibitory synapses. *Neuron.* 2011;70(3):385–409.
72. Ghosh H, Auguadri L, Battaglia S, Simone Thirouin Z, Zemoura K, Messner S, et al. Several posttranslational modifications act in concert to regulate gephyrin scaffolding and GABAergic transmission. *Nat Commun.* 2016;7:13365.
73. Tyagarajan SK, Ghosh H, Yevens GE, Imanishi SY, Zeilhofer HU, Gerrits B, et al. Extracellular signal-regulated kinase and glycogen synthase kinase 3beta regulate gephyrin postsynaptic aggregation and GABAergic synaptic function in a calpain-dependent mechanism. *J Biol Chem.* 2013;288(14):9634–47.
74. Jacob TC, Bogdanov YD, Magnus C, Saliba RS, Kittler JT, Haydon PG, et al. Gephyrin regulates the cell surface dynamics of synaptic GABAA receptors. *J Neurosci.* 2005;25(45):10469–78.
75. Kneussel M, Brandstätter JH, Laube B, Stahl S, Müller U, Betz H. Loss of postsynaptic GABA(A) receptor clustering in gephyrin-deficient mice. *J Neurosci.* 1999;19(21):9289–97.
76. Jamain S, Quach H, Betancur C, Rastam M, Colineaux C, Gillberg IC, et al. Mutations of the X-linked genes encoding neuroligins NLGN3 and NLGN4 are associated with autism. *Nat Genet.* 2003;34(1):27–9.
77. Gauthier J, Siddiqui TJ, Huashan P, Yokomaku D, Hamdan FF, Champagne N, et al. Truncating mutations in NRXN2 and NRXN1 in autism spectrum disorders and schizophrenia. *Hum Genet.* 2011;130(4):563–73.
78. Lionel AC, Vaags AK, Sato D, Gazzellone MJ, Mitchell EB, Chen HY, et al. Rare exonic deletions implicate the synaptic organizer Gephyrin (GPHN) in risk for autism, schizophrenia and seizures. *Hum Mol Genet.* 2013;22(10):2055–66.
79. Prasad A, Merico D, Thiruvahindrapuram B, Wei J, Lionel AC, Sato D, et al. A discovery resource of rare copy number variations in individuals with autism spectrum disorder. G3 (Bethesda). 2012;2(12):1665–85.
80. Wu HF, Chen PS, Chen YJ, Lee CW, Chen IT, Lin HC. Alleviation of N-methyl-D-aspartate receptor-dependent long-term depression via regulation of the glycogen synthase kinase-3beta pathway in the amygdala of a valproic acid-induced animal model of autism. *Mol Neurobiol.* 2017;54(7):5264–76.
81. Qin L, Ma K, Wang ZJ, Hu Z, Matas E, Wei J, et al. Social deficits in Shank3-deficient mouse models of autism are rescued by histone deacetylase (HDAC) inhibition. *Nat Neurosci.* 2018;21(4):564–75.
82. Martin HG, Manzoni OJ. Late onset deficits in synaptic plasticity in the valproic acid rat model of autism. *Front Cell Neurosci.* 2014;8:23.
83. Suyama S, Ralevski A, Liu ZW, Dietrich MO, Yada T, Simonds SE, et al. Plasticity of calcium-permeable AMPA glutamate receptors in Pro-opiomelanocortin neurons. *Elife.* 2017;6:e25755.
84. Stoner R, Chow ML, Boyle MP, Sunkin SM, Mouton PR, Roy S, et al. Patches of disorganization in the neocortex of children with autism. *N Engl J Med.* 2014;370(13):1209–19.
85. Banerjee A, Garcia-Oscos F, Roychowdhury S, Galindo LC, Hall S, Kilgard MP, et al. Impairment of cortical GABAergic synaptic transmission in an environmental rat model of autism. *Int J Neuropsychopharmacol.* 2013;16(6):1309–18.
86. Martin M, Hill C, Bewley S, MacLennan AH, Braillon A. Transgenerational adverse effects of valproate? A patient report from 90 affected families. *Birth Defects Res.* 2022;114(1):13–6.
87. Takeshima H, Ushijima T. Accumulation of genetic and epigenetic alterations in normal cells and cancer risk. *NPJ Precis Oncol.* 2019;3:7.
88. Klengel T, Dias BG, Ressler KJ. Models of intergenerational and transgenerational transmission of risk for psychopathology in mice. *Neuropsychopharmacology.* 2016;41(1):219–31.
89. Bale TL, Baram TZ, Brown AS, Goldstein JM, Insel TR, McCarthy MM, et al. Early life programming and neurodevelopmental disorders. *Biol Psychiatry.* 2010;68(4):314–9.

90. Mouat JS, LaSalle JM. The promise of DNA methylation in understanding multigenerational factors in autism spectrum disorders. *Front Genet.* 2022;13:831221.
91. Jiang S, He M, Xiao L, Sun Y, Ding J, Li W, et al. Prenatal GABAB receptor agonist administration corrects the inheritance of autism-like core behaviors in offspring of mice prenatally exposed to valproic acid. *Front Psychiatry.* 2022;13:835993.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

